

Paper No. _____
Filed: January 24, 2018

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AUROBINDO PHARMA USA INC.,
Petitioner,

v.

Andrx Corporation,
Andrx Labs, LLC
Andrx Laboratories, Inc.
Andrx Laboratories (NJ), Inc.
Andrx EU Ltd.
Andrx Pharmaceuticals, LLC,
Teva Pharmaceutical Industries Inc.
Patent Owner(s).

Case No. IPR 2018-_____
Patent No. 6,790,459

*PETITION FOR INTER PARTES REVIEW OF U.S. PATENT NO. 6,790,459
UNDER 35 U.S.C. §§ 311-319 AND 37 C.F.R. §§ 42.1-.80, 42.100-.123*

Mail Stop “PATENT BOARD”
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O Box 1450
Alexandria, VA 22313-1450

Table of Contents

	Page
I. PAYMENT OF FEES	1
II. INTRODUCTION	1
A. Commercial Product Said to Be Covered by the '459 Patent	1
B. Brief Overview of the '459 Patent	2
C. Brief Overview of the Prosecution History	3
D. Critical Date	10
III. STANDING (37 C.F.R. 42.104(A)); PROCEDURAL STATEMENTS	10
IV. MANDATORY NOTICES UNDER 37 C.F.R. § 42.8	10
A. Designation of Lead and Back-up Counsel (37 C.F.R. § 42.8(b)(3) and (b)(4)	12
B. Notice of Service Information (37 C.F.R. § 42.8(b)(4))	13
V. IDENTIFICATION OF CHALLENGE (37 C.F.R. § 42.104(B))	13
VI. STATEMENT OF THE PRECISE RELIEF REQUESTED AND THE REASONS THEREFOR IN RESPECT OF EACH CHALLENGED CLAIM (37 C.F.R. § 42.22(A))	14
VII. PERSON OF ORDINARY SKILL IN THE ART IN RESPECT OF U.S. PATENT NO. 6,790,459 B1	15
VIII. BACKGROUND OF TECHNOLOGY AND PRIOR ART	16
IX. CLAIM CONSTRUCTION	17
A. “metformin”	18
B. “therapeutically effective reduction”	18
C. “C_{max}”	18
D. “T_{max}”	18
E. “T_{1/2}”	19
F. “AUC”	19

G.	“a patient”	19
H.	“mean”,	20
I.	“controlled release carrier”	20
J.	“passageway”	20
X.	DETAILED ANALYSIS OF GROUNDS FOR TRIAL.....	21
A.	Brief Summary of the Prior Art Cited Herein	21
B.	Grounds for Unpatentability	29
XI.	NO OBJECTIVE INDICIA OF NON-OBVIOUSNESS.....	60
XII.	CONCLUSION	60
XIII.	CERTIFICATE OF COMPLIANCE	62
XIV.	APPENDIX - LIST OF EXHIBITS	63

I. PAYMENT OF FEES

Pursuant to 37 C.F.R. §§ 42.15(A) AND 42.103 the fee paid at the time of filing this petition, is charged to Deposit Account 506744. Should any further fees be required by the present Petition, the Patent Trial and Appeal Board (“PTAB”) is hereby authorized to charge the above referenced Deposit Account.


II. INTRODUCTION

Pursuant to the provisions of 35 U.S.C. § 311 and § 6 of the Leahy-Smith America Invents Act (“AIA”), and to 37 C.F.R. Part 42, Aurobindo Pharma Inc., (“Petitioner”) hereby requests inter partes review of United States Patent No. 6,790,459 to Xiu Cheng *et al.*, (“the '459 patent,” Ex. 1001), which issued on Sept. 14, 2004, and is currently assigned to Andrx Labs LLC., which is owned by Teva Pharmaceutical Industries Inc. (collectively “Patent Owner(s)”).

A. Commercial Product Said to Be Covered by the '459 Patent

FORTAMET® (metformin hydrochloride) Extended-Release Tablets contain an oral antihyperglycemic drug used in the management of type 2 diabetes. Metformin hydrochloride (N,N-dimethylimidodicarbonimidicdiamide hydrochloride) is a member of the biguanide class of oral antihyperglycemics and is not chemically or pharmacologically related to any other class of oral

antihyperglycemic agents. The empirical formula of metformin hydrochloride is $C_4H_{11}N_5 \cdot HCl$ and its molecular weight is 165.63. Its structural formula is:



B. Brief Overview of the '459 Patent.

U.S. Patent No. 6,790,459 (the '459 patent") issued with 21 claims of which claim 1 is the sole independent claim. Claim 1 of the '459 patent is directed to a method for lowering blood glucose levels in human patients needing treatment for non-insulin-dependent diabetes mellitus (NIDDM), comprising orally administering to human patients on a once-a-day basis at least one oral controlled release dosage form comprising an effective dose of metformin, or a pharmaceutically acceptable salt thereof, and an effective amount of a controlled release carrier to control the release of said metformin, or pharmaceutically acceptable salt thereof, from the dosage form within specified pharmacokinetic (PK) parameters. The pharmacokinetic parameters of the once a day dosage include a mean time to maximum plasma concentration (T_{max}) of metformin at from 5.5 to 7.5 hours after administration following dinner; a mean AUC_{0-24} of 22590 ± 3626 ng·hr/ml and a

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.